Ischemia- Modified Albumin Levels in the Sudden Hearing Loss
Launched by YUZUNCU YIL UNIVERSITY · Oct 10, 2018
Trial Information
Current as of June 25, 2025
Unknown status
Keywords
ClinConnect Summary
Sudden hearing loss is an ENT emergence occurring within 72 hours, with sensorineural hearing loss of more than 30 dB on three consecutive frequencies. The incidence of this disease was 5-20 / 100000. The etiology of this disease has not been fully elucidated. In addition, viral infections, tumors, autoimmune diseases and vascular insufficiency have been suggested as etiologic factors by different researchers. There is no definitive routine treatment modality in the world because the etiology is not fully established. However, corticosteroid treatment is a well-accepted agent for the treatm...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admission with sensorineural hearing loss
- Exclusion Criteria:
- • cardiovascular disease
- • hypertension
- • diabetes mellitus
- • malignancy
- • chronic inflammatory disease
- • kidney failure
- • liver failure
About Yuzuncu Yıl University
Yüzüncü Yıl University is a distinguished institution committed to advancing healthcare through rigorous clinical research. With a strong emphasis on innovation and collaboration, the university actively engages in various clinical trials aimed at enhancing medical knowledge and improving patient outcomes. Its dedicated research teams are equipped with state-of-the-art facilities and a diverse array of expertise, fostering an environment that promotes ethical standards and scientific excellence. Yüzüncü Yıl University is dedicated to contributing to the global medical community by translating research findings into practical applications for improved health and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials